$MED
MEDIFAST INC Stock $med

$med Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414066472 Filed on November 10, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q4
Revenue	$62.30M	$69.02M	$70.30M
YoY Change	-11.38%	-20.19%	-15.5%
Cost Of Revenue	$17.30M	$18.28M	$18.30M
YoY Change	-5.46%	-15.46%	-10.29%
Gross Profit	$45.00M	$50.73M	$51.90M
YoY Change	-13.29%	-21.77%	-17.36%
Gross Profit Margin	72.23%	73.51%	73.83%
Selling, General & Admin	$40.80M	$44.14M	$41.90M
YoY Change	-2.63%	-23.23%	-28.98%
% of Gross Profit	90.67%	87.01%	80.73%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.100M	$2.256M	$0.00
YoY Change		-16.2%	-100.0%
% of Gross Profit	4.67%	4.45%	0.0%
Operating Expenses	$40.80M	$44.14M	$41.90M
YoY Change	-2.63%	-23.23%	-29.22%
Operating Profit	$4.200M	$6.590M	$10.00M
YoY Change	-58.0%	-10.33%	177.78%
Interest Expense	$300.0K	$149.0K	$200.0K
YoY Change	50.0%	-10.78%	100.0%
% of Operating Profit	7.14%	2.26%	2.0%
Other Income/Expense, Net	-$300.0K	$918.0K	-$500.0K
YoY Change	-40.0%	73.53%
Pretax Income	$4.200M	$7.508M	$9.800M
YoY Change	-57.14%	-4.7%	172.22%
Income Tax	$1.600M	$2.227M	$2.600M
% Of Pretax Income	38.1%	29.66%	26.53%
Net Earnings	-$3.400M	$4.855M	$5.300M
YoY Change	-164.15%	-14.42%	178.95%
Net Earnings / Revenue	-5.46%	7.03%	7.54%
Basic Earnings Per Share		$0.39
Diluted Earnings Per Share	-$283.3K	$0.39	$389.7K
COMMON SHARES
Basic Shares Outstanding	12.06M shares	12.46M shares	13.88M shares
Diluted Shares Outstanding		12.57M shares

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.10M	$83.26M	$104.2M
YoY Change	-25.99%	-35.95%	4.26%
Cash & Equivalents	$24.46M	$27.63M	$36.38M
Short-Term Investments	$52.64M	$55.63M	$67.80M
Other Short-Term Assets	$6.800M	$3.900M	$5.600M
YoY Change	21.43%	34.48%	16.67%
Inventory	$15.74M	$16.20M	$17.54M
Prepaid Expenses
Receivables	$1.650M	$2.400M	$942.0K
Other Receivables	$5.000M	$900.0K	$0.00
Total Short-Term Assets	$81.91M	$79.10M	$91.95M
YoY Change	-10.92%	-25.98%	3.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.48M	$36.00M	$34.48M
YoY Change	-2.9%	-12.48%	-14.04%
Goodwill
YoY Change
Intangibles			$0.00
YoY Change			-100.0%
Long-Term Investments
YoY Change
Other Assets	$497.0K	$300.0K	$231.0K
YoY Change	115.15%	-15.73%	-79.72%
Total Long-Term Assets	$34.00M	$36.20M	$40.70M
YoY Change	-16.46%	-12.86%	-2.35%
TOTAL ASSETS
Total Short-Term Assets	$81.91M	$79.10M	$91.95M
Total Long-Term Assets	$34.00M	$36.20M	$40.70M
Total Assets	$115.9M	$115.3M	$132.7M
YoY Change	-12.62%	-22.3%	1.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.20M	$27.10M	$12.00M
YoY Change	1.67%	-10.56%	-57.45%
Accrued Expenses	$5.800M		$4.800M
YoY Change	20.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K	$0.00
YoY Change		0.0%	-100.0%
Total Short-Term Liabilities	$26.94M	$27.30M	$27.10M
YoY Change	-0.58%	-10.66%	-5.73%
LONG-TERM LIABILITIES
Long-Term Debt	$200.0K	$300.0K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$2.800M		$0.00
YoY Change
Total Long-Term Liabilities	$3.000M	$300.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.94M	$27.30M	$27.10M
Total Long-Term Liabilities	$3.000M	$300.0K	$0.00
Total Liabilities	$35.43M	$32.80M	$34.23M
YoY Change	3.51%	-11.49%	-13.25%
SHAREHOLDERS EQUITY
Retained Earnings	$78.90M	$82.26M	$97.70M
YoY Change	-19.25%	-13.61%	27.66%
Common Stock	$1.144M		$13.00K
YoY Change	8700.0%		-18.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00		$0.00
YoY Change			-100.0%
Treasury Stock Shares	0.000 shares		0.000 shares
Shareholders Equity	$80.48M	$82.55M	$98.42M
YoY Change
Total Liabilities & Shareholders Equity	$115.9M	$115.3M	$132.7M
YoY Change	-12.62%	-22.28%	1.84%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q4
OPERATING ACTIVITIES
Net Income	-$3.400M	$4.855M	$5.300M
YoY Change	-164.15%	-14.42%	178.95%
Depreciation, Depletion And Amortization	$2.100M	$2.256M	$0.00
YoY Change		-16.2%	-100.0%
Cash From Operating Activities	$900.0K	$8.300M	$8.300M
YoY Change	-89.16%	29.69%	1283.33%
INVESTING ACTIVITIES
Capital Expenditures	-$2.900M	-$1.200M	-$2.800M
YoY Change	3.57%	-60.0%	300.0%
Acquisitions
YoY Change
Other Investing Activities	-$300.0K	$8.200M	$3.000M
YoY Change	-110.0%	8100.0%	-178.95%
Cash From Investing Activities	-$3.200M	$7.100M	$200.0K
YoY Change	-1700.0%	-344.83%	-104.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-900.0K	-19.70M	-20.10M
YoY Change	-95.52%	-9950.0%	-3450.0%
NET CHANGE
Cash From Operating Activities	900.0K	8.300M	8.300M
Cash From Investing Activities	-3.200M	7.100M	200.0K
Cash From Financing Activities	-900.0K	-19.70M	-20.10M
Net Change In Cash	-3.200M	-4.300M	-11.60M
YoY Change	-72.41%	-216.22%	241.18%
FREE CASH FLOW
Cash From Operating Activities	$900.0K	$8.300M	$8.300M
Capital Expenditures	-$2.900M	-$1.200M	-$2.800M
Free Cash Flow	$3.800M	$9.500M	$11.10M
YoY Change	-65.77%	1.06%	753.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	222000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27101000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36382000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13852155	shares
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1246000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	18059000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	31420000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2890000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	1957000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	91954000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40336000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	360000	USD
CY2013Q4	us-gaap	Assets Assets	132650000	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	26780000	USD
CY2013Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	99000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	474000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6659000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	34234000	USD
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	282000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	82258000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	82552000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	115339000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.34
CY2014Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	4795000	USD
CY2014Q3	us-gaap	Retail Related Inventory RetailRelatedInventory	1000000	USD
CY2014Q3	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	1073000	USD
CY2014Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9481000	USD
CY2014Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	141000	USD
	us-gaap	Net Income Loss NetIncomeLoss	18679000	USD
	med	Effect Of Dilutive Common Stock Equivalent EffectOfDilutiveCommonStockEquivalent	-103062	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13955217	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.35
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	67764	shares
CY2014Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	55088000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	66514000	USD
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	690000	USD
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1442000	USD
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-217000	USD
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-263000	USD
CY2014Q3	us-gaap	Interest Receivable InterestReceivable	67000	USD
CY2013Q4	us-gaap	Interest Receivable InterestReceivable	109000	USD
CY2014Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	55628000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	67802000	USD
CY2014Q3	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	27997000	USD
CY2013Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	31420000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0161	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6315	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q3	med	Allowance For Doubtful Accounts Receivable And Sales Returns Current AllowanceForDoubtfulAccountsReceivableAndSalesReturnsCurrent	573000	USD
CY2013Q4	med	Allowance For Doubtful Accounts Receivable And Sales Returns Current AllowanceForDoubtfulAccountsReceivableAndSalesReturnsCurrent	647000	USD
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12368249	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13143309	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12058314	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13115642	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	70542	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	67764	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5051	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.11
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2489000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	529000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.07
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	24.61
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M4D
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	458340	USD
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	41517	USD
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	700000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.19
	us-gaap	Revenues Revenues	279595000	USD
	us-gaap	Revenues Revenues	241404000	USD
CY2013Q3	us-gaap	Revenues Revenues	86480000	USD
CY2014Q3	us-gaap	Revenues Revenues	73992000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	69403000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	62194000	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	21627000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	19076000	USD
	med	Selling General And Administrative Expenses Excluding Depreciation Depletion And Amortization SellingGeneralAndAdministrativeExpensesExcludingDepreciationDepletionAndAmortization	175712000	USD
	med	Selling General And Administrative Expenses Excluding Depreciation Depletion And Amortization SellingGeneralAndAdministrativeExpensesExcludingDepreciationDepletionAndAmortization	149831000	USD
CY2013Q3	med	Selling General And Administrative Expenses Excluding Depreciation Depletion And Amortization SellingGeneralAndAdministrativeExpensesExcludingDepreciationDepletionAndAmortization	54812000	USD
CY2014Q3	med	Selling General And Administrative Expenses Excluding Depreciation Depletion And Amortization SellingGeneralAndAdministrativeExpensesExcludingDepreciationDepletionAndAmortization	46721000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7912000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7332000	USD
CY2013Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2692000	USD
CY2014Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2256000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	898000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	906000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	27466000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	24536000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	7878000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	6845000	USD
CY2013Q3	us-gaap	Assets Assets	148396000	USD
	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	270000000	USD
	us-gaap	Gross Profit GrossProfit	210192000	USD
	us-gaap	Gross Profit GrossProfit	179210000	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	64853000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	54916000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	183624000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	157163000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	57504000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48977000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	26568000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	22047000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7349000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	5939000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	317000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	445000	USD
CY2013Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	167000	USD
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	149000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	581000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2044000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	362000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	757000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8787000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7994000	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2205000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1990000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	171000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	304000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-146000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	217000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	592000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	32000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	459000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-221000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-421000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	272000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-605000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-221000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-421000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	272000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-605000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	18458000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	16121000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5945000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4250000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1858000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	51000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	33894000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	337000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	949000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1772000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1858000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-47000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1269000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-85000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	17000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-216000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1108000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3353000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1851000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1261000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-953000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-764000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-64000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2117000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	310000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1682000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1006000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	34093000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	24561000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	7416000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	23367000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	21576000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	19700000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1215000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-22804000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	674000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8644000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4208000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3587000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	166000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	19000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	23000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	322000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	51000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	33894000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-3246000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-33986000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8043000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8751000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39937000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47980000	USD
	us-gaap	Interest Paid InterestPaid	49000	USD
	us-gaap	Interest Paid InterestPaid	104000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	10143000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	10211000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 13.5pt"> <div>1.</div> </td> <td style="TEXT-ALIGN: justify"> <div>Basis of Presentation</div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 13.5pt" align="justify">The condensed unaudited interim consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included. The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 13.5pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 13.5pt" align="justify">The results of operations for the three months and nine months ended September 30, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014. The accompanying condensed unaudited interim consolidated financial statements should be read in conjunction with the 2013 audited financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2013 (“2013 Form 10-K”).</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3	us-gaap	Prepaid Taxes PrepaidTaxes	907000	USD
CY2013Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	MEDIFAST INC
	dei	Entity Central Index Key EntityCentralIndexKey	0000910329
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	MED
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12060558	shares
	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2778	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	27.16
	med	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expiration Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirationWeightedAverageRemainingContractualTerm1	P10Y
	med	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vesting Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestingPeriod	P3Y

Files In Submission

Name	View Source	Status
0001144204-14-066472-index-headers.html	Edgar Link	pending
0001144204-14-066472-index.html	Edgar Link	pending
0001144204-14-066472.txt	Edgar Link	pending
0001144204-14-066472-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
med-20140930.xml	Edgar Link	completed
med-20140930.xsd	Edgar Link	pending
med-20140930_cal.xml	Edgar Link	unprocessable
med-20140930_def.xml	Edgar Link	unprocessable
med-20140930_lab.xml	Edgar Link	unprocessable
med-20140930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v392739_10q.htm	Edgar Link	pending
v392739_ex31-1.htm	Edgar Link	pending
v392739_ex31-2.htm	Edgar Link	pending
v392739_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MED
MEDIFAST INC Stock $med

2014 Q4 Form 10-Q Financial Statement

#000114420414066472 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED MEDIFAST INC Stock $med

2014 Q4 Form 10-Q Financial Statement

#000114420414066472 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED
MEDIFAST INC Stock $med